Time to Buy into Target's (TGT) Post Earnings Rally?
https://www.zacks.com/stock/news/2236363/time-to-buy-into-target-s-tgt-post-earnings-rally?cid=CS-ZC-FT-stocks_in_the_news-2236363
Mar 05, 2024 - Target (TGT) headlined Tuesday's trading session with its stock spiking +12% after exceeding fourth quarter expectations this morning.
0
GitLab (GTLB) Posts Gain in Q4, Beats Revenue Estimates
https://www.zacks.com/stock/news/2236154/gitlab-gtlb-posts-gain-in-q4-beats-revenue-estimates?cid=CS-ZC-FT-analyst_blog|earnings_article-2236154
Mar 05, 2024 - GitLab's (GTLB) fiscal fourth-quarter results benefit from solid subscription revenue growth driven by expanding clientele.
0
PlayAGS (AGS) Posts Breakeven Q4 Earnings, Tops on Revenues
https://www.zacks.com/stock/news/2236794/playags-ags-posts-breakeven-q4-earnings-tops-on-revenues?cid=CS-ZC-FT-analyst_blog|earnings_article-2236794
Mar 06, 2024 - PlayAGS' (AGS) fourth-quarter 2023 results reflect double-digit growth across all three operating segments.
0
Vail Resorts (MTN) to Post Q2 Earnings: What's in the Offing?
https://www.zacks.com/stock/news/2237552/vail-resorts-mtn-to-post-q2-earnings-what-s-in-the-offing?cid=CS-ZC-FT-analyst_blog|earnings_preview-2237552
Mar 07, 2024 - Vail Resorts' (MTN) fiscal second-quarter performance is likely to have benefited from digital initiatives, increased spending per visit and stability in the advance commitment program.
0
Golar LNG (GLNG) Shares Improve 3.6% Post Q4 Earnings Beat
https://www.zacks.com/stock/news/2238770/golar-lng-glng-shares-improve-3-6-post-q4-earnings-beat?cid=CS-ZC-FT-analyst_blog|earnings_article-2238770
Mar 11, 2024 - Golar LNG's (GLNG) fourth-quarter 2023 revenues improve year over year.
0
Lexicon (LXRX) Dips on Post Hoc Analysis Data on Sotagliflozin
https://www.zacks.com/stock/news/2240235/lexicon-lxrx-dips-on-post-hoc-analysis-data-on-sotagliflozin?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2240235
Mar 13, 2024 - New post hoc analysis of data from Lexicon's (LXRX) phase III study shows improvements in glycemic control when treated with sotagliflozin for type 1 diabetes and chronic kidney disease.
0
Latham Group (SWIM) Posts Breakeven Q4 Earnings, Tops on Sales
https://www.zacks.com/stock/news/2240228/latham-group-swim-posts-breakeven-q4-earnings-tops-on-sales?cid=CS-ZC-FT-analyst_blog|earnings_article-2240228
Mar 13, 2024 - Latham Group's (SWIM) fourth-quarter fiscal 2023 results reflect dismal volumes of in-ground swimming pools.
0
Post Holdings (POST) Gains on Solid Buyouts & Pricing Actions
https://www.zacks.com/stock/news/2240200/post-holdings-post-gains-on-solid-buyouts-pricing-actions?cid=CS-ZC-FT-analyst_blog|rank_focused-2240200
Mar 13, 2024 - Post Holdings (POST) intends to strengthen its business on the back of strategic acquisitions. The company is benefiting from strategic pricing actions undertaken to counter inflation.
0
Philip Morris (PM) Advances Smoke-Free Evolution With New Launch
https://www.zacks.com/stock/news/2240745/philip-morris-pm-advances-smoke-free-evolution-with-new-launch?cid=CS-ZC-FT-analyst_blog|company_news_-_corporate_actions-2240745
Mar 14, 2024 - Philip Morris (PM) unveils the IQOS ILUMA i to continue offering enhanced alternatives to consumers. Philip Morris is well-placed to become a majority smoke-free company.
0
Accenture (ACN) to Post Q2 Earnings: Here's What to Expect
https://www.zacks.com/stock/news/2242259/accenture-acn-to-post-q2-earnings-here-s-what-to-expect?cid=CS-ZC-FT-analyst_blog|earnings_preview-2242259
Mar 18, 2024 - Accenture's (ACN) second-quarter fiscal 2024 revenues and earnings are expected to have declined from the year-ago levels.
0